CVS vs PPCB · P/E 16, rev $402.07B vs P/E 0.0, $3.9M cap
CVS Health Corp (CVS) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
PPCB does not have a complete income-statement cache yet.
CVS currently screens at market cap $86.20B and trailing P/E 16.3. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the CVS and PPCB stock pages for the full models.
Not investment advice.